Welcome to our dedicated page for Abivax S.A. SEC filings (Ticker: AAVXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Abivax S.A.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Abivax S.A.'s regulatory disclosures and financial reporting.
Abivax SA (ABVX) — Schedule 13D/A Amendment No. 3: Sofinnova Crossover I SLP and affiliated reporting persons updated their ownership and disclosed recent open‑market sales of American Depositary Shares. As of September 30, 2025, they report holding 4,334,739 Ordinary Shares, representing approximately 5.6% of shares outstanding, and 8,399,478 voting rights, representing approximately 9.4% of voting rights. The base figures cited are 77,830,067 Ordinary Shares and 89,189,666 voting rights outstanding as of September 30, 2025.
The filing lists sales completed in multiple transactions: on October 28, 2025, 522,948 ADSs at a weighted average price of $94.00 per share and 67,929 ADSs at a weighted average price of $95.42; on October 29, 2025, 606,293 ADSs at a weighted average price of $94.00 and 2,830 ADSs at a weighted average price of $95.34. The reporting persons state the shares were acquired for investment purposes and reserve the right to buy or sell as permitted by law.
ABVX: A stockholder filed a Form 144 to sell up to 1,200,000 ADS, with an aggregate market value of $111,300,000. The proposed sale is listed for approximately 10/28/2025 through Leerink Partners on the NASDAQ.
The securities were acquired in the IPO on 10/20/2023, with 1,200,000 ADS purchased from the issuer and paid in cash on 10/24/2023. Shares outstanding were 77,800,000; this is a baseline figure, not the amount being offered.